NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past,
present, and future. - Abstract - Europe PMC Sign in | Create an account https://orcid.org
Europe PMC Menu About Tools Developers Help Contact us Helpdesk Feedback Twitter Blog
Tech blog Developer Forum Europe PMC plus Search life-sciences literature (43,682,208
articles, preprints and more) Search Advanced search Feedback This website requires cookies,
and the limited processing of your personal data in order to function. By using the site you are …

Idiopathic pulmonary fibrosis (IPF) is a devastating illness for which current therapy is
minimally effective. If medical therapy for IPF is going to improve over the next decade,
controlled clinical trials will be needed to evaluate new drugs and treatment regimens. To
date, very few multicenter trials have been conducted in IPF compared with diseases with a
similar mortality (Table 1). Current therapy, which usually includes corticosteroids with or
without a cytotoxic agent, has evolved without the support of large, well-controlled clinical …